An experimental drug could help to improve movement for patients with spinal cord injuries. NVG-291, an injectable peptide, has been tested in a phase 2 trial with eligible patients — some of whom ...
An experimental drug could help to improve movement for patients with spinal cord injuries. NVG-291, an injectable peptide, has been tested in a phase 2 trial with eligible patients — some of whom ...
Hosted on MSN
Nervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment
Nervgen Pharma Corp ((NGENF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback